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Abstract
Purpose Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is 
limited. Academic tertiary referral centers offer cutting-edge diagnosis and treatment; however, in many parts of the region, 
patients are managed by non-specialists with limited resources. Due to many factors including lack of awareness and lack of 
prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate 
cancer at diagnosis. The aim of these recommendations is to assist clinicians in managing patients with different levels of 
access to diagnostic and treatment modalities.
Methods The first Advanced Prostate Cancer Consensus Conference (APCCC) satellite meeting for the Middle East was held 
in Beirut, Lebanon, November 2017. During this meeting a consortium of urologists, medical oncologists, radiation oncolo-
gist and imaging specialists practicing in Lebanon, Syria, Iraq, Kuwait and Saudi Arabia voted on a selection of consensus 
questions. An additional workshop to formulate resource-stratified consensus recommendations was held in March 2019.
Results Variations in practice based on available resources have been proposed to form resource-stratified recommendations 
for imaging at diagnosis, initial management of localized prostate cancer requiring therapy, treatment of castration-sensitive/
naïve advanced prostate cancer and treatment of castration-resistant prostate cancer.
Conclusion This is the first regional consensus on prostate cancer management from the Middle East. The following rec-
ommendations will be useful to urologists and oncologists practicing in all areas with limited access to specialist multi-
disciplinary teams, diagnostic modalities and treatment resources.
Keywords Prostate cancer · Middle East · Resource-stratified recommendations · Consensus · Multidisciplinary
Introduction
The 2017 Advanced Prostate Cancer Consensus Conference 
(APCCC) was held in St Gallen, Switzerland in March 2017 
during which a panel of 60 international experts voted on 
150 questions addressing controversial topics in prostate 
cancer management [1]. The first APCCC Satellite Meeting 
for the Middle East was held in Beirut, Lebanon in Novem-
ber 2017 in conjunction with the Middle East Prostate Can-
cer Consortium (MEPCC) comprised of urologists, medical 
oncologists, radiation oncologists and imaging specialists 
largely from Lebanon, Syria and Iraq with expert urologists 
from Kuwait and Saudi Arabia joined by the co-chair of 
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the APCCC Dr Aurelius Omlin from St Gallen. During this 
satellite meeting, faculty members presented brief clinical 
updates with a focus on topics of particular relevance to 
the Middle East region and all attendees were asked to vote 
on a selection of the APCCC questions (see supplemental 
material). Consensus was declared if ≥ 75% of participants 
Fig. 1  Areas of consensus 
(≥ 75% agreement) APCCC 
2017 compared to Beirut Satel-
lite Meeting 2017
Lymph node dissection in men with cN0 cM0 high-risk prostate cancer undergoing 
prostatectomy
APCCC 2017 Beirut Satellite 2017 Concordance?
84% 76% Yes
In men post-prostatectomy without lymph node involvement on surgical pathology (pN0), 
with undetectable postoperave PSA and who have recovered urinary connence, do you 
recommend adjuvant radiaon therapy in in case of:
Posive surgical margins
• Yes, in the majority of paents
APCCC 2017 Beirut Satellite 2017 Concordance?
45% 81% No
If you recommend adjuvant radiaon therapy in men with pN1 disease (adequate sampling) 
post-prostatectomy, what field of radiaon therapy do you recommend in the majority of 
men?
• Prostac bed plus whole pelvis
APCCC 2017 Beirut Satellite 2017 Concordance?
97% 82% Yes
Do you recommend adding ADT in combinaon with salvage radiaon therapy?
• Yes, in the majority of paents
APCCC 2017 Beirut Satellite 2017 Concordance?
61% 83% No
Oligometastac + Bone Health
Definion of oligometastac disease
A clinically meaningful definion of oligometastac prostate cancer that influences 
treatment decision (local treatment of all lesions +/- systemic therapy) includes:
• Only paents with a limited number of bone and/or lymph nodes metastases that 
can be treated with local therapy
APCCC 2017 Beirut Satellite 2017 Concordance?
61% 81% No
Do you recommend a dental check for CRPC paents with bone metastases prior to starng 
an osteoclast-targeted therapy?
• Yes, in the majority of paents
APCCC 2017 Beirut Satellite 2017 Concordance?
74.8% 82% Yes
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who did not vote for “unqualified” or “abstain” and chose 
the same option [2] (see Fig. 1). The meeting was organized 
by the Continuing Medical Education office of the American 
University of Beirut and co-chaired by Dr Deborah Mukherji 
(medical oncologist) and Dr Raja Khauli (urologist and 
panel member for the APCCC 2017 meeting).
The manuscript published following the APCCC 2017 
provides a guide for clinicians to assist in the discussions 
Castraon-sensive/naive metastac prostate cancer
For men who are suitable for chemotherapy:
Do you recommend Docetaxel in addion to ADT in men with de novo metastac 
castraon-sensive/naive prostate cancer and high volume disease as defined by 
CHAARTED (visceral metastases and/or ≥4 bone lesions with ≥1 beyond vertebral bodies and 
pelvis)?
• Yes, in the majority of paents
APCCC 2017 Beirut Satellite 2017 Concordance?
96% 95% Yes
Do you recommend Docetaxel in addion to ADT in with metastac castraon-
sensive/naive disease relapsing aer prior treatment for localized prostate cancer and 
with high volume disease as per CHAARTED (visceral metastases and/or ≥4 bone lesions 
with ≥1 beyond vertebral bodies and pelvis)? 
• Yes, in the majority of paents
APCCC 2017 Beirut Satellite 2017 Concordance?
74% 89% No
Castraon-Resistant Prostate Cancer
What is your preferred first-line mCRPC treatment opon in the majority of asymptomac 
or minimally symptomac men who did NOT receive Docetaxel in the castraon-
sensive/naive seng?
• Abiraterone or Enzalutamide
APCCC 2017 Beirut Satellite 2017 Concordance?
86% 87% Yes
What is your preferred first-line mCRPC treatment opon in the majority of symptomac
men who DID receive Docetaxel in the castraon-sensive/naive seng?
• Abiraterone or Enzalutamide
APCCC 2017 Beirut Satellite 2017 Concordance?
90% 86% Yes
What is your preferred second-line mCRPC treatment opon in the majority of men with 
symptomac mCRPC who had progressive disease as best response to first-line Abiraterone 
or Enzalutamide?
• Taxane
APCCC 2017 Beirut Satellite 2017 Concordance?
96% 85% Yes
Fig. 1  (continued)
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with patients as part of a multidisciplinary decision-making 
process particularly in areas lacking clear evidence from 
randomized clinical trials on which to base treatment rec-
ommendations [1]. Due to the rapid changes in prostate 
cancer management since this publication of the APCCC 
recommendations in 2017, an additional workshop was held 
in Beirut in March 2019 to update our resource-stratified 
consensus recommendations specifically for the Middle East 
using a modified-Delphi method. Resource-stratified rec-
ommendations are based on expert-opinion and structured 
in-line with a simplified version of the resource-stratifica-
tion levels proposed by the Breast Health Global Initiative 
(BHGI) and adopted by the American Society of Clinical 
Oncology (ASCO) [3]. We have stratified our recommenda-
tions between two levels rather than four since the choice 
of treatment in the Middle East region is not just depend-
ent on financial resources but also available expertise. We 
did not feel that for the needs of practitioners in the region, 
making finer discrimination between the four levels would 
be of added value since there would be considerable over-
lap and repetition. We emphasize the importance of referral 
to centers with appropriate expertise as needed wherever 
possible. Significant variations in coverage of health-care 
costs exist both within and between countries. Systems of 
governmental health-care coverage, private insurance and 
self-payment operate in parallel. In a region lacking access 
to specialist multidisciplinary care in many areas, these rec-
ommendations are not designed to replace evidence-based 
guidelines, however, may assist in management decisions 
for patients with different levels of access to diagnostic and 
treatment modalities.
Epidemiology of prostate cancer 
in the Middle East
Prostate cancer is the second most commonly diagnosed 
cancer in men worldwide, with an incidence of 1,276,106 
in 2018 and the 5th most common cause of cancer mortality 
worldwide with 358,989 fatalities in 2018, according to Glo-
bocan [4]. Australia, Europe and Northern America have the 
highest age-standardized incidence rate of prostate cancer in 
2018, when Asia has the lowest incidence rate [4].
A dramatic increase in prostate cancer incidence has 
been globally identified in the past few decades since the 
introduction of PSA screening [5]. In 2018, prostate cancer 
has been identified as the most common cancer in men in 
all the continents except for Asia where it is the fifth most 
common cancer (Table 1) [4]. Nevertheless, it is worth 
noting that the reported incidence in the past 5 years in 
the US has dropped since the United States Preventative 
Services Task Force (USPSTF) issued a recommendation 
What is your preferred second-line mCRPC treatment opon in the majority of men with 
symptomac mCRPC and secondary (acquired) resistance (inial response followed by 
progression) aer use of first-line Abiraterone or Enzalutamide?
• Taxane
APCCC 2017 Beirut Satellite 2017 Concordance?
90% 100% Yes
What is your preferred third-line mCRPC treatment opon in the majority of men with 
mCRPC, progressing on or aer second-line Docetaxel for mCRPC AND prior treatment with 
Abiraterone or Enzalutamide?
• Cabazitaxel
APCCC 2017 Beirut Satellite 2017 Concordance?
61% 81% No
Fig. 1  (continued)
Table 1  Incidence of Prostate cancer in 2018 worldwide
Area Incidence of prostate 
cancer in 2018
Age-standardized 
ratio per 100,000
Europe 449,761 62.1
Asia 297,215 11.5
North America 234,278 73.7
Latin America and the 
Caribbean
190,385 56.4
Africa 80,971 26.6
Oceania 23,496 79.1
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against screening in 2012, with concomitant rise in locally 
advanced disease and nodal metastasis at diagnosis [6].
Partly due to the lack of awareness and regular screen-
ing in the Middle East, plus potential deficiencies in 
regional cancer registries, the incidence of prostate can-
cer is low compared to the rest of the world. Lebanon, a 
country with advanced tertiary care referral centers, has 
the highest rate of prostate cancer in the region due to high 
use of PSA screening with 39.3 per 100,000 in most recent 
data in 2018 (Table 2).
Diagnosis and management of high‑risk 
localized and locally advanced prostate 
cancer
In common with many parts of the world, cancer care in the 
Middle East is highly variable with specialist multidisci-
plinary care limited to few academic medical centers in the 
region. PSA screening is not routinely practiced, and our 
panelists reported that a significant proportion of men with 
prostate cancer present with locally advanced and metastatic 
disease. Few prospective data are available, however, a sin-
gle-institution study from the American University of Bei-
rut, Lebanon showed that up to 25% of patients presented 
with locally advanced or metastatic disease including 16% 
with M1 disease [7].
Imaging at diagnosis
Recent data from the PRECISION and PROMIS studies 
have established the value of performing magnetic reso-
nance imaging (MRI) prior to prostate biopsy in men with 
suspected prostate cancer, however, our panel discussed the 
fact that few radiologists in the region have specific training 
in reading prostate MRI according to the prostate imaging 
reporting and data system (PIRADS) classification [8, 9]. 
For patients who have access to MRI pre-biopsy, targeted 
and random biopsies from the prostate are recommended, 
either “cognitive” targeting or image-guided according to the 
expertise of the treating team. For patients without access 
to MRI pre-biopsy, trans-rectal ultrasound (TRUS)-guided 
biopsy remains standard of care. If TRUS-guided biopsy is 
not available, patients should be referred to centers offering 
this modality; finger-directed biopsy of the prostate should 
only be performed in patients with grossly advanced local 
disease. For patients with high-risk disease at diagnosis, the 
panel considered that the current standard of care remains 
bone scan and cross-sectional imaging with either computed 
tomography (CT) or MRI. However, for patients with access 
to positron emission tomography (PET)-PSMA or whole-
body MRI scans (so-called ‘next-generation imaging’), 
these imaging modalities are increasingly being utilized 
for staging, particularly PET-PSMA in Lebanon and Saudi 
Arabia (Table 3). To date there is no evidence that the use 
of next-generation imaging for staging improves outcomes. 
The panel discussed the controversy surrounding the man-
agement of patients found to have distant metastatic disease 
on next-generation imaging since treatment guidelines are 
based on patients staged with conventional modalities. We 
recommend that patients diagnosed with stage 4 disease 
on next-generation imaging should not be offered radical 
Table 2  Incidence of prostate cancer in the Middle East region, 2018
Middle East country Incidence of prostate 
cancer in 2018
Age-standardized 
ratio per 100,000
Lebanon 1503 39.3
Iraq 556 6.6
Jordan 397 14.7
Kuwait 221 21.6
Oman 145 12.7
Qatar 73 15.5
Saudi Arabia 607 6.1
Syria 1136 20.1
Algeria 2578 13.0
Egypt 3109 9.5
Libya 317 15.6
Morocco 3990 22.7
Tunisia 819 12.3
Table 3  Resource-stratified recommendations for imaging at diagnosis of prostate cancer
Resource-level Imaging prior to 
biopsy
Biopsy Imaging to rule-out metastatic disease in high-risk patients
Basic/limited None TRUS-guided biopsy or finger 
directed in grossly advanced 
local disease
Bone scan plus or minus CT or MRI
Enhanced/maximal MRI Targeted plus random
Cognitive or fusion-image 
guided if local expertise and 
access
Bone scan plus CT
PET-PSMA if accessible
Whole-body MRI if accessible and local expertise
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prostatectomy outside clinical trials, however, given recent 
data from the STAMPEDE trial, radiation to the primary in 
low-volume metastatic disease is now standard of care and 
should be offered [10].
Initial management of localized/locally advanced 
disease
The definition of high-risk localized and locally advanced 
prostate cancer varies between guidelines and inclusion cri-
teria for key clinical trials such as the STAMPEDE study 
[1]. For the APCCC 2017 St Gallen meeting, the European 
Association of Urology (EAU) guideline definition was used 
(high-risk localized disease: PSA level > 20 ng/ml, or Glea-
son score > 7 or > T2c; locally advanced disease: any PSA 
level, any Gleason score, cT3-4, or cN+).
In regions with limited access to primary care physi-
cians, the majority of men with prostate cancer present to 
a general urologist. Due to lack of formal multidisciplinary 
tumor board meetings outside academic medical centers, the 
urologist who makes the diagnosis of prostate cancer is usu-
ally responsible for setting the treatment plan and making 
referrals to other specialists. Our panel recommends that 
ideally all men with locally advanced prostate cancer should 
be discussed with and seen by a radiation oncologist and a 
medical oncologist for formulation of the management plan 
(Table 4). Physicians with no access to an on-site tumor 
board can present cases virtually or in person at institutions 
where multidisciplinary meetings are being held. Other 
options include direct telephone/email contact between local 
urologists, medical oncologists and radiation oncologists. 
Multidisciplinary discussion is essential at diagnosis but also 
important at relapse following radical local therapy.
The St Gallen APCCC 2017 conference did not address 
the choice of primary treatment for high-risk localized and 
locally advanced prostate cancer. In the Middle East region 
since many patients are diagnosed with prostate cancer by 
general urologists, our panelists noted that in some cases 
men with locally advanced or metastatic disease at diagno-
sis are offered androgen-deprivation therapy (ADT) alone 
and not referred for radiation or additional systemic therapy 
despite new data suggesting a survival benefit to treatment 
intensification for this group of patients [11–14]. Our pan-
elists also discussed that at the other end of the spectrum, 
patients presenting with locally advanced disease may be 
offered surgery as part of a multimodality treatment; patients 
have to be informed about the high possibility of requir-
ing adjuvant radiation therapy. Our group is working on the 
development of patient information in regional languages 
describing different treatment modalities and their potential 
toxicities.
Surgical management of high‑risk localized 
and locally advanced prostate cancer 
plus or minus adjuvant radiation therapy
Our panel discussed the fact that younger patients without 
medical co-morbidities are increasingly opting for pri-
mary surgery; however, education about the possible need 
for adjuvant radiation therapy should be discussed with 
all patients, ideally with referral to a radiation oncologist 
(Table 4). Our panelists agreed with the APCCC 2017 con-
sensus regarding pelvic lymph node (PLND) dissection for 
the majority of men with high-risk prostate cancer under-
going radical prostatectomy (Fig. 1). Extended PLND dis-
section to the level of the common iliac arteries was also 
a consensus recommendation, however, our panel qualified 
that this should only be undertaken by surgeons with appro-
priate training and expertise.
For centers with appropriate resources and expertise, 
open radical prostatectomy and robotic-assisted laparoscopic 
prostatectomy are options to discuss with patients. Ideally, 
Table 4  Resource-stratified recommendations for initial management of localized prostate cancer requiring therapy
Resource-level Multidisciplinary discussion Surgical management of localized 
prostate cancer
Radiation for localized prostate cancer
Basic/limited Review of published guidelines
Discussion of options with patient by 
primary physician
Telephone/email discussion between 
urologist/oncologist/radiation oncolo-
gist
Patient referral to other specialists for 
management
Open radical prostatectomy ± pelvic 
lymph node dissection (for non-low 
risk patients)
External-beam radiation therapy with 
addition of ADT for intermediate-
high risk disease
Enhanced/maximal Face-to-face tumor board with imaging 
and pathology review
Patient referral to urologist, oncologist 
and radiation oncologist to discuss 
options for management
Consider radical prostatectomy (open or 
robotic-assisted laparoscopic depend-
ing on local expertise)
Extended lymph node dissection with 
for men with high-risk disease
Consider IMRT with ADT for inter-
mediate/high-risk disease ± moder-
ate hypofractionation
Consider brachytherapy if available 
and appropriate
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patients with high-risk and locally advanced disease request-
ing surgery should be referred to high-volume centers. Our 
panel stressed the importance of patient education regarding 
rigorous follow-up post-prostatectomy using PSA monitor-
ing to ensure that patients who will require salvage radia-
tion therapy will be identified at an appropriately early time 
period with low PSA levels (see salvage radiation section).
Adjuvant radiation after radical prostatectomy
Patients post-prostatectomy with an undetectable post-
operative PSA but high-risk pathologic features should be 
considered for adjuvant radiation therapy; however, the 
decision between offering adjuvant radiation versus early 
salvage radiation is controversial and an overall survival 
benefit associated with pure adjuvant treatment has not been 
demonstrated [15]. The results of the on-going RADICALS 
(NCT00541047) and RAVES (NCT00860652) studies which 
have been designed to compare adjuvant and early savage 
radiation therapy may inform future practice.
Our panel reached consensus that the majority of high-
risk patients with positive surgical margins should be 
offered adjuvant radiation therapy. The importance of giv-
ing adjuvant therapy based on positive margins alone has 
been debated in the literature; however, recent data suggest 
that the risk of recurrence and even prostate cancer-specific 
mortality may be higher in patients with positive margins 
and high-risk disease [16]. For patients with seminal vesi-
cle involvement or Gleason grade group 5 tumors, or even 
certain patients with node-positive tumors but no other high-
risk features and undetectable post-operative PSA, the option 
of adjuvant versus early salvage radiation can be discussed. 
Adjuvant treatment for node-negative disease is generally 
given to the prostate bed and pelvis with ADT for 6 months 
[17]; however, consensus was not reached in our panel on 
this issue, as results from the NRG/RTOG 0534 trial are 
still not fully published. Our panel reached consensus that 
adjuvant radiation for men with node-positive disease should 
be given to the prostate bed plus whole pelvis with at least 
18–36 months of ADT.
The results of randomized studies comparing purely adju-
vant versus salvage radiation therapy are awaited, however, 
in terms of cost-effectiveness in low-resource settings, if 
appropriate PSA monitoring can be undertaken our panel 
recommends deferring radiation to the early salvage setting 
in men with evidence of rising PSA post-prostatectomy.
Salvage radiation after radical prostatectomy
Men who fail to achieve an undetectable PSA (< 0.2 ng/ml) 
post-prostatectomy [18] and those with rising PSA after an 
initial drop to undetectable levels are candidates for salvage 
radiation. Current data suggest that starting early salvage 
radiation therapy before the PSA rises to 0.5 will have better 
outcomes [19, 20]. Our panel reflected that many patients 
do not have appropriate follow-up of post-prostatectomy 
and present for salvage with much higher PSA levels. On 
the other extreme, patients may opt to measure their PSA 
post-operatively at very frequent intervals and present with 
evidence of rising PSA at lower levels than the standard 
0.2 ng/ml definition of biochemical recurrence. The panel 
considered that recommended salvage radiation in men with 
a confirmed rising PSA prior to the 0.2 ng/ml threshold is 
appropriate (two successive rises of PSA) [21].
The panel discussed that if resources are available, a 
PET-PSMA can be useful in the context of patients present-
ing post-prostatectomy with PSA > 0.5 ngml to evaluate for 
nodal or distant metastatic disease [22] and tailor the need 
and extent of radiation salvage.
A consensus was reached regarding the recommendation 
of ADT (LHRH-Agonist preferred over anti-androgen) with 
salvage radiation therapy; however, there was no consensus 
over the duration and in general 6–12 months are recom-
mended according to the commonly used regimens in pub-
lished trials [17, 23].
Systemic therapy for node‑positive disease 
post‑prostatectomy
The management of patients with high-risk, locally advanced 
prostate cancer found to have positive lymph nodes post-rad-
ical prostatectomy is a controversial issue. Recent data from 
the STAMPEDE study and NRG Oncology/RTOG 0521 
study [11, 12, 24] were discussed at our update workshop 
held in March 2019. These studies provide data to support 
the use of docetaxel for six cycles or abiraterone for 2 years 
with radiation and ADT for 2 years in selected patients. Our 
panel reached consensus that ideally men found to have 
node-positive disease post-prostatectomy should see both a 
radiation oncologist and a medical oncologist for discussion 
regarding radiation plus systemic therapy (Table 5).
Table 5  High-risk features to 
consider adjuvant systemic 
therapy (docetaxel/abiraterone)
STAMPEDE criteria At least 2 of: T 3 or 4, PSA ≥ 40 ng/ml, Gleason 8–10
Stage  pTany pN + M0
NRG Oncology/RTOG 0521 study criteria Gleason 9–10 independent of PSA or T stage
Gleason 7–8 and PSA ≥ 20 ng/ml with any T stage
Gleason score 8 and PSA < 20 ng/ml with T stage ≥ T2
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Definitive radiation therapy for high‑risk and locally 
advanced prostate cancer
For patients undergoing definitive radiation therapy for 
high-risk and locally advanced prostate cancer, techniques 
vary depending on local resources and expertise (Table 4). 
For men with access to enhanced or maximal resources 
in the region, several centers are now offering Intensity 
Modulated Radiation Therapy (IMRT) which has benefits 
in terms of minimizing toxicity related to treatment [25]. 
Recent ASTRO/ASCO/AUA guidelines recommend moder-
ate hypofractionation across risk groups, however, the task 
force strongly recommended image-guided radiation therapy 
and avoidance of non-modulated three-dimensional confor-
mal techniques with any hypofractionated approach [26].
For patients with high-risk disease receiving definitive 
radiation therapy, 36 months of ADT was not shown to be 
superior to 18 months of ADT. In this randomized study, 
overall survival was not significantly different between 
the two groups; however, non-inferiority could not be 
established [27]. Our panel currently recommend at least 
18 months ADT for the majority of high-risk patients, noting 
that improvements in imaging and the early identification 
of patients with metastatic disease is likely to refine patient 
selection.
Investigators from The American University of Beirut 
Medical Center (AUBMC) have shown that nadir PSA at 
0.06 ng/ml is a strong predictor of outcome in a cohort of 
patients with intermediate and high-risk localized prostate 
cancer [28].
Management of advanced 
castration‑sensitive/naïve prostate cancer
For patients with biochemical recurrence after radical pros-
tatectomy and salvage radiation or primary radiation therapy, 
evidence-based recommendations for the timing of initiation 
of ADT have not been well defined. Recent clinical trials 
have shown a benefit in terms of prolongation of metastasis-
free survival from the addition of enzalutamide, apaluta-
mide or darolutamide in non-metastatic castration-resistant 
prostate cancer (nmCRPC) [29–31]. As yet, these medica-
tions are not widely available in the Middle East for this 
indication, however, may be considered proof of principle 
that earlier control of androgen receptor (AR) signaling in 
patients with a low burden of disease in the advanced setting 
may improve outcomes. Regarding the timing of initiation of 
ADT in men after failure of local therapy, consensus was not 
reached, however, 34% of panel recommend starting ADT in 
the majority of patients with confirmed PSA progression and 
58% recommended starting ADT in a minority of selected 
patients for example PSA ≥ 4 ng/ml with doubling time less 
than 6 months. Only 8% recommend starting ADT only on 
detection of metastatic disease.
Our panel discussed the fact that recent trials in the set-
ting of nmCRPC used conventional imaging for staging and 
that with the wider used of PET-PSMA we are seeing fewer 
patients with rising PSA and no radiologic evidence of meta-
static disease. We discussed the limited sensitivity of PET-
CT at PSA levels less than 0.5 ng/ml [22].
Oligometastatic disease
As previously discussed, a high proportion of patients in 
the Middle East present with advanced prostate cancer at 
diagnosis. This may be due to various reasons including lack 
of screening, awareness and health-care access. The man-
agement of so-called “oligometastatic” prostate cancer is a 
controversial topic discussion at most international meetings 
and the subject of on-going prospective research. Our panel 
discussed the fact that since many patients in the region lack 
access to uro-oncology specialists or clinical trials, this is 
an area that is being addressed largely at specialist centers 
after multidisciplinary discussion. With the increasing use of 
PET-PSMA scans at diagnosis particularly in Lebanon, we 
are seeing more patients who may be candidates for intensi-
fication of both local and systemic therapy.
The APCCC 2017 panel did not reach consensus on the 
definition of oligometastatic disease with 10% of the experts 
stating that they did not believe that oligometastatic disease 
exists as a clinically meaningful entity. All of our panel in 
Beirut considered oligometastatic disease to be a clinically 
meaningful entity. There was consensus that patients with 
a limited number of bone and/or lymph nodes who could 
be treated with local therapy would constitute a clinically 
meaningful definition of oligometastatic prostate cancer 
that may influence treatment decisions (local treatment of 
all lesions ± systemic therapy). Where available, our panel 
recommends either PET-PSMA or whole-body MRI scan 
(depending on local expertise) for the confirmation of oli-
gometastatic disease.
For the management of patients diagnosed with de novo 
oligometastatic disease with no prior treatment for prostate 
cancer, in the absence of clinical trials, 50% of our panelists 
voted for radical treatment of lesions including the primary 
with ADT for 24–26 months plus or minus systemic treat-
ment with docetaxel or abiraterone, however, consensus was 
not reached (Table 4).
Metastatic castration‑sensitive/naïve prostate 
cancer (not considered oligometastatic)
For men progressing following local therapy or presenting 
with de novo metastatic disease, data from the CHAARTED, 
STAMPEDE and LATTITUDE studies have conclusively 
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demonstrated a survival benefit from the addition of sys-
temic therapy to standard ADT [11–14]. It is clear from the 
data that patients with a higher disease burden derive the 
greatest benefit from additional systemic therapy; however, 
the definition of high-volume disease has not been consistent 
across trials. Our panel considered that a practical defini-
tion of high-volume metastatic disease for multidisciplinary 
decision making is the definition used in the CHAARTED 
study of visceral metastasis or ≥ 4 bone lesions with ≥ 1 
beyond the vertebral bodies and pelvis with the caveat that 
any imaging modality can be used.
We reached consensus that for men suitable for chem-
otherapy, docetaxel or abiraterone in addition to ADT 
should be recommended for castration-sensitive/naïve 
patients with high-volume metastatic disease as defined 
above (either de novo at diagnosis or at relapse following 
local therapy).
The cost-effectiveness of abiraterone plus prednisone 
until progression versus six cycles of docetaxel was dis-
cussed. No formal head-to-head comparisons have been 
made, however, the authors of the STAMPEDE study have 
published an indirect comparison between patients who were 
randomized to either the ADT plus docetaxel arm of the 
trial and the ADT plus abiraterone arm of the trial during 
the same time period. The investigators report no difference 
in overall survival between the two groups [32]. Despite the 
fact that generic forms of abiraterone will soon be avail-
able in the region, six cycles of docetaxel are currently sig-
nificantly more cost-effective compared to abiraterone plus 
prednisone until progression [33]. The panel considered this 
to be the treatment of choice for patients who are candidates 
for chemotherapy.
For patients with low-volume disease as defined by 
the CHAARTED study, the choice of additional systemic 
therapy is more controversial. Long-term survival analysis 
of the CHAARTED study confirmed a significant survival 
benefit associated with docetaxel for patients with high-
volume disease, however, no survival benefit was observed 
for patients with low-volume disease. In view of these data, 
many consider the evidence base to be stronger for the use 
of abiraterone for low-volume hormone-sensitive metastatic 
disease [11, 13, 34]. In view of the associated cost and lim-
ited access to this treatment in most of the region, our panel 
recommend that treatment with docetaxel should be consid-
ered, particularly for patients with poor adverse prognostic 
factors such as high Gleason grade group [32] (Table 6).
Recently published data from the STAMPEDE study have 
also clarified the role of radiation to the prostate in patients 
with advanced disease. Local radiation did not improve sur-
vival for unselected patients; however, a prespecified analy-
sis showed that survival was improved (from 73 to 81% at 
3 years) in those with a low metastatic burden [10].
Our panel reached consensus that baseline imaging and 
follow-up imaging at PSA nadir/completion of six cycles 
of docetaxel should be performed with further imaging 
at progression defined by confirmed PSA rise or clinical 
progression. Next-generation imaging was recommended 
if available, however, the standard of care remains CT and 
bone scans.
Management of castration‑resistant 
prostate cancer
Access to treatment modalities for metastatic castration-resist-
ant prostate cancer (mCRPC) in the region varies according 
to country and financial coverage. In Lebanon, the ministry 
of public health covers abiraterone or enzalutamide (but not 
Table 6  Resource-stratified recommendations for the treatment of castration-sensitive/naïve advanced prostate cancer
Resource-level Oligometastatic Low-volume metastatic disease (not consid-
ered oligometastatic)
High-volume metastatic disease
Basic/limited ADT—surgical/medical
Consider radiation to 
prostate if local treat-
ment has not been 
given
ADT—surgical/medical
Consider radiation to prostate if local treat-
ment has not been given
ADT—surgical/medical, consider docetaxel 6 
cycles
Enhanced/maximal Consider PET-PSMA/
whole-body MRI
Radiation to prostate if 
local treatment has not 
been given
Consider radia-
tion to metastatic 
lesions + ADT mini-
mum 24–36 months
Consider abiraterone 
2 years with radiation 
or docetaxel 6 cycles
Radiation to prostate if local treatment has not 
been given
ADT—lifelong (surgical/medical)
Consider abiraterone until progression (if 
available) or docetaxel 6 cycles
No local therapy indicated unless for palliation
ADT—lifelong (surgical/medical)
Consider docetaxel 6 cycles (preferred in terms 
of cost-effectiveness) or abiraterone until 
progression if available
690 World Journal of Urology (2020) 38:681–693
1 3
sequential therapy), docetaxel and cabazitaxel for eligible 
patients. We are not aware of any data suggesting excess toxic-
ity or frequent need for dose modifications for men in the region 
compared to published data. Sipuleucel-T and radium-223 are 
not available in the region. Lutetium-PSMA therapy is available 
in Lebanon, however, since this is not FDA or EMEA approved 
it is not covered by third-party payers.
A randomized phase II study has reported non-inferior-
ity in terms of PSA metrics between low-dose abiraterone 
250 mg with a low-fat meal compared to standard dosing 
with 1000 mg fasting in patients CRPC [35]. Additional 
studies are required to assess the long-term efficacy of the 
strategy, however in resource-limited environments this 
could potentially be considered.
Our panel agreed with the APCCC 2017 consensus that 
asymptomatic men with mCRPC should receive abirater-
one or enzalutamide as first-line treatment whether they 
had received ADT alone (87%) or ADT plus docetaxel in 
the castration-naïve setting (86%). This was qualified by 
the recommendation that in men with progression less than 
6 months following the completion of 6 cycles of docetaxel 
in the castration-naïve setting, cabazitaxel could be consid-
ered. The panel also discussed the need to consider biopsy in 
patients progressing with visceral disease, particularly with a 
low PSA who may be developing androgen-independent dis-
ease and in some cases neuro-endocrine differentiation [36].
For asymptomatic men with mCRPC and progression 
on abiraterone or enzalutamide, the panel preferred taxane 
chemotherapy as a second-line option (56%), however, con-
sensus was not reached.
We reached consensus that for symptomatic patients 
with acquired resistance to first-line abiraterone/enzaluta-
mide, taxane chemotherapy should be offered (100%), and 
that cabazitaxel should be offered as third-line treatment for 
the majority of men with mCRPC progressing following 
second-line docetaxel and prior treatment with abiraterone/
enzalutamide (81%). The panel discussed the possible use 
of docetaxel re-challenge in selected patients with mCRPC 
when cabazitaxel is not available (Table 7).
Our panel preferred baseline imaging and follow-up 
imaging at PSA nadir and again at progression, however, 
consensus was not reached and some opted for baseline 
imaging only and monitoring by PSA alone with imaging at 
progression. Next-generation imaging was preferred if avail-
able, otherwise CT and bone scan remain standard imaging 
modalities. Our panel reflected that in many cases, lines of 
therapy are switched based on PSA progression alone with-
out imaging; however, ideally patient should be monitored 
by cross-sectional imaging.
Use of osteoclast‑targeted therapy
Our panel reflected that the monitoring of bone health for 
patients with prostate cancer treated with ADT in the region is 
sub-optimal. A useful resource is the FRAX online calculator 
(https ://www.sheffi eld.ac.uk/FRAX/) that is freely available 
and has been validated in several middle-eastern populations 
[37]. All patients on ADT should be prescribed calcium and 
vitamin D supplementation with monitoring for osteoporosis.
The RANK-ligand inhibitor denosumab and bisphos-
phonate zoledronic acid are both available in the region; 
however, denosumab is only approved for the treatment of 
osteoporosis and not advanced cancer with bone metastasis 
in some countries. Neither drug has been shown to improve 
survival or influence progression-free survival, however, in 
the setting of mCRPC both drugs can protect against skel-
etal-related events (SREs) [38–40]. There is no evidence to 
support the use of osteoclast-targeted therapy in the non-
metastatic setting or metastatic castration-naïve patients for 
SRE prevention (Table 8).
Our panel reached consensus that osteoclast-targeted ther-
apy for SRE prevention should be recommend in the majority 
of patient with mCRPC and bone metastasis. A dental check-
up should be performed prior to starting therapy to decrease 
the risk of osteonecrosis of the jaw. Most of the panel recom-
mend zoledronic acid for 2 years which can be given every 
3 months and may be more cost-effective that denosumab that 
should be given every 4 weeks continuously [41].
Table 7  Resource-stratified recommendations for the treatment of castration-resistant prostate cancer
Resource-level Asymptomatic mCRPC Symptomatic mCRPC Second-line mCRPC Third-line
mCRPC
Basic/limited Docetaxel Docetaxel Docetaxel re-challenge in 
selected patients
Supportive care
Supportive care
Enhanced/maximal Abiraterone/enzalutamide
Docetaxel
Docetaxel
Abiraterone/enzalutamide
Docetaxel/cabazitaxel
Abiraterone/Enzalutamide
Consider biopsy—if low 
PSA/visceral disease
Cabazitaxel
Consider biopsy—if 
low PSA/visceral 
disease
Consider PSMA-based 
theranostics if avail-
able
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Conclusion
This satellite meeting of the APCCC–MEPCC is the first 
regional consensus on prostate cancer management in the 
Middle East that has attempted to set out recommendations 
based on availability of local resources and expertise. Our 
group acknowledges that participants were largely from Leb-
anon and from tertiary referral centers in the region. This 
reflects our management approach, in particular our use of 
novel diagnostic imaging modalities such as PET-PSMA 
which is widely available in Lebanon. We hope this review 
of controversial issues in prostate cancer management will 
be useful to the non-specialist urologist or oncologist prac-
ticing in all areas with limited access to specialist multidis-
ciplinary teams, diagnostic and treatment modalities.
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